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2. ABSTRACT 
Adherence to antiretroviral therapy among women living with HIV with previous participation 
in prevention of mother-to-child transmission programmes in Moshi, Tanzania 
 
Linnea Jönsson  
Degree Project, Programme in Medicine, 2018. 
Department of Infectious Diseases, Gothenburg, Sweden.  
 
Background 
To optimize adherence to antiretroviral therapy (ART) in prevention of mother-to-child 
transmission (PMTCT) programmes, it is important to know ART adherence patterns among 
women. Increased knowledge of this can increase compliance to ART and further on decrease 
transmission of HIV from mother to child.  
 
Aim 
Investigate the effects of previous participation in PMTCT programmes on ART adherence 
among women living with HIV attending the PMTCT programme. 
 
Methods 
This cohort study was conducted at health centres in Moshi, Tanzania, March–April 2018. A semi-
structured questionnaire was administered to women attending Care and Treatment Clinics and 
antenatal clinics. In addition, information from medical charts was collected. Adherence was 
defined as number of missed doses during the last week. Good adherence was defined as an intake 
of 95% or more. 
 
Results 
Twenty-one participants were enrolled. Nineteen women (90%) were adherent to their medication 
during the last week. Eight women (38%) had previously participated in a PMTCT programme and 
among those, two women had ended prematurely. There was no significant difference in ART 
adherence among mothers participating in the PMTCT programme for the first time compared to 
those who had participated before (p = 0.51). 
 
Conclusion 
Adherence rate among the women attending the PMTCT programme in Moshi is high. No 
correlation between previous participation in PMTCT programme and ART adherence was 
found. 
 
Key words PMTCT, HIV, Medication adherence, Antiretroviral therapy  
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3. BACKGROUND  
3.1 EPIDEMIOLOGY  
In 2016, 36.7 million people in the world were living with HIV (human immunodeficiency 
virus) and 19.5 million of those were on antiretroviral therapy (ART) (1). HIV/AIDS (acquired 
immune deficiency syndrome) is globally the major reason of mortality among women of 
reproductive age (2). Although methods of prevention are known, 1.8 million people were newly 
infected during 2016 (1). Sub-Saharan Africa still remains the most HIV-affected region in the 
world and accounts for two-thirds of people living with HIV worldwide (3). 
Tanzania is a country in eastern Sub-Saharan Africa with a population of 55.6 million (4). The 
first cases of HIV appeared in Tanzania in 1983 and since then the HIV epidemic has affected the 
entire society (5). In 2016, Tanzania had 1.4 million adults and children living with HIV and in 
the past ten years the prevalence merely has decreased from 6.6% to 4.7% among adults (15–49 
years old), despite increased knowledge and roll-out of treatment (6). 
3.2 HIV TRANSMISSION FROM MOTHER TO INFANT 
Transmission of HIV can occur during sex, via blood products, through intravenous drug abuse, 
and from mother to infant (7). So called vertical transmission (mother to infant) can occur in-
utero, intrapartum, or postnatally through breastfeeding with a mutual definition called mother-
to-child transmission (MTCT) (8). 
The risk of transmitting HIV from mother to infant is approximately 15–25% during pregnancy 
and delivery if no prophylactic interventions are initiated, with an additional 10–15% risk if the 
mother breastfeeds the baby (9). Interventions during pregnancy, delivery, and breastfeeding can 
reduce this risk to below 0.5% (10). Mainly, these interventions involve ART for the mother and 
prophylactic antiretroviral drugs to the child but also interventions of suitable feeding practices 
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(8). For instance, breastfeeding is fundamental in some regions in the world, since mothers can 
feed their infant with breast milk regardless of sanitation status and access to safe water (11). 
High plasma viral load in the mother is the most important risk factor for transmission of HIV 
from mother to child during pregnancy, intrapartum, and postnatally (7). Other risk factors for 
MTCT during pregnancy are prematurity (before gestation week 34), sexually transmitted 
infections (STIs), and low CD4+ levels (12) (13). Extended period from membrane rupture to 
delivery (14), chorioamnionitis (15), and vaginal delivery if the mother’s viral load is high are 
some intrapartum risk factors (16). After delivery, mixed feeding (defined as giving both 
breastmilk and other fluids and/or food to an infant) to infants under the age of six months 
increases the risk of transmission (17). Mastitis in the mother and oral thrush in the infant have 
also been found to be risk factors postnatally (18, 19). 
3.3 ANTIRETROVIRAL THERAPY AND ADHERENCE 
ART is a combination of different antiretroviral drugs (ARVs), combined with the intention to 
decrease HIV RNA levels and prevent progression of the HIV disease (20). Six classes of 
antiretroviral drugs with different mechanism are registered. Generally, a combination of three 
ARVs is used to treat HIV. The six classes of ARVs are nucleoside reverse transcriptase 
inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors 
(PIs), integrase inhibitors (INSTIs), fusion inhibitors (FIs), and chemokine receptor antagonists 
(CCR5 antagonists). The exact combination for a specific patient depends on side-effects and 
resistance patterns for example (7).    
To prevent MTCT of HIV it is important that pregnant women receive ART which can suppress 
the virus to undetectable levels (7). In 2016, the coverage of ART in pregnant women in 
Tanzania was 84% (6). 
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For breastfeeding or pregnant women, recommended first-line therapy is two NRTIs and one 
NNRTI (Tenofovir + Lamivudine/Emtricitabine + Efavirenz). Two measurements within three 
months with viral loads above 1000 copies/ mL after six months with new ART should be 
defined as viral failure. Recommended second-line therapy consists of two NRTIs + one 
ritonavir-boosted PI (21). 
Adherence to ART can be explained as the voluntary ability to take the HIV medications in the 
exact manner written in the drug prescription which includes correct dosage and frequency. A 
well-recognized definition of good adherence is an intake of 95% or more of the doses. This 
definition is based on a study from 2000 when patients receiving PIs (with adherence over 95%) 
suppressed their viral loads to <400 copies/mL (22). In contrast, a meta-analysis from 2016, 
showed that adherence slightly lower than 95% also lead to viral suppression and the 95% 
definition should not prevent patients from receiving ART according to the authors (23). 
Since the strongest risk factor for MTCT of HIV is the mothers viral load, adherence to treatment 
is of utmost importance (24). Unfortunately, optimal ART adherence has been shown to be a 
problem during pregnancy and postnatally, with approximately 25% of pregnant women having 
suboptimal adherence. Reasons for non-adherence are both economic and physical stress, 
depression, alcohol and drugs, and difficulties with medications (25).  Factors associated with 
good adherence during pregnancy have been shown to be disclosure of HIV status and having 
treatment support (26). Inadequate knowledge about ART and prevention of mother-to-child 
transmission (PMTCT) are factors having negative impact on adherence among women living 
with HIV (27). Stigma on a community level has also been shown to be associated with 
suboptimal adherence (28). 
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3.4 RECOMMENDATIONS FROM WHO 
Since 2015, WHO recommends lifelong ART to all pregnant and breastfeeding women regardless 
of clinical stage of disease or CD4+ T-lymphocyte levels. This approach is called Option B+ even 
though there are no other options since 2015 (21). This has been implemented in Tanzania since 
2013 (29).  
During pregnancy, WHO recommendations include extensive HIV testing, pregnancy care to 
avoid hypertension and pre-eclampsia, and testing for other STIs (21). Delivery with supervision 
of competent caregivers is also recommended and the child should be washed from blood after 
delivery. WHO does not recommend elective caesarean sections in societies with limited 
resources to mothers living with HIV unless other obstetric indications occur (21). 
The newborn should be given prophylaxis with one or two ARVs for 4-12 weeks depending on if 
the risk of transmission is considered high and if the mother breastfeeds the baby or uses 
commercial breastmilk substitutes (21, 30). 
3.5 PMTCT PROGRAMME IN MOSHI  
The HIV testing rate is high among pregnant women in the Kilimanjaro region. In 2017, nearly 
99% of pregnant women received HIV counselling, were tested for HIV, and received the result 
(31). Since 2004, Kilimanjaro Christian Medical Centre (KCMC) is offering free ART (32). All 
mothers living with HIV are recommended ART. CD4-levels and viral load measurements are 
available, but resistance-testing is very limited at KCMC due to the high cost (33). In 2015-2016, 
91% of women living in the Kilimanjaro region gave birth in a health facility (34). 
All pregnant women are offered a HIV-test at their first antenatal care visit. If a woman is 
diagnosed with HIV, she is included in the PMTCT programme and should thereafter attend the 
clinic once every month during pregnancy. The PMTCT programme is a part of the antenatal care 
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in Moshi. Blood samples are collected for analysis of HIV viral load, liver function tests, 
tuberculosis screening, and screening for STIs. In addition, regular delivery preparations will be 
done (35).  
After delivery, the mother will continue to attend the PMTCT programme. Breastfeeding 
recommendations for all mothers in Moshi are exclusive breastfeeding for six months and after 
that breastfeeding for one year in combination with solid food and/ or commercial breastmilk 
substitutes. If the child is HIV-exposed (has an HIV-positive mother) and not infected one year 
after delivery the mother should stop breastfeeding. The child will be tested for HIV six weeks 
after delivery with PCR (HIV RNA), six weeks after cessation of breastfeeding with PCR (HIV 
RNA), and a confirmation test at the age of 18 months should be done with an antibody test (35). 
3.6 MEDICAL RELEVANCE 
To increase adherence to ART among pregnant and breastfeeding women in Tanzania it is central 
to analyse adherence patterns. Participation in a PMTCT programme has been offered to all 
pregnant women with HIV in Moshi Tanzania since 2004, but the outcome of this has never been 
studied. Therefore, the aim of my master thesis is to evaluate if there is a difference in ART 
adherence between women with previous participation in PMTCT programmes compared to 
women participating in the PMTCT programme for the first time. This knowledge will hopefully 
result in targeted efforts to increase the adherence and further on decrease the transmission of 
HIV to children.  
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4. AIMS 
 
The primary aim was to investigate the effect of previous participation in PMTCT programmes 
on ART adherence among women living with HIV attending the PMTCT programme in Moshi. 
Secondary aims were to analyse if previous participation in PMTCT programmes had an effect 
on the HIV status of the child/children and to investigate if socioeconomic status, education level, 
age, and knowledge of ART and PMTCT programmes affect level of adherence to ART.  
5. MATERIAL AND METHODS 
 
5.1 STUDY DESIGN:  
This cross-sectional cohort study took place in Moshi, in northern Tanzania at the Care and 
Treatment Clinics (CTC) and antenatal clinics (ANC) at KCMC and Pasua Health Centre. 
KCMC is a large referral hospital and Pasua Health Centre is a public clinic with focus on people 
in disadvantaged socioeconomic classes.  
Participants were enrolled in the waiting room at the clinics from the 7th of March until 18th of 
April, a total of 7 weeks. The women received oral information about the study, had the 
opportunity to ask questions, and thereafter gave their consent to participate in the study. 
5.2 PARTICIPANTS:  
o Inclusion criteria: Women living with HIV that were pregnant or had an infant younger than 
two months, attending CTC for follow-up in their PMTCT programme and women coming 
for their first delivery at antenatal care. 
o Exclusion criteria: Mothers with an infant older than two months. 
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The number of patients differed from 0 to 6 per week. There was no non-completion due to 
denial of participation. 
5.3 DATA COLLECTION:  
To collect data, a semi-structured questionnaire was designed. When I arrived to Moshi I was told 
that my ethical application was denied so I could not participate in the distribution of the 
questionnaires. My tutor in Tanzania, Dr Philemon was conducting a study during the period of 
my stay in Moshi, analysing factors influencing adherence to breastfeeding amongst HIV-
positive women which received ethical clearance from KCMUCo. He was going to collect data 
on ART also, even though it was not the primary objective so we incorporated my questionnaire 
in the one from this larger study. Due to this, my study had to have the same inclusion criteria’s 
as the study conducted by my tutor. Since my ethical approval was denied, the start of the field 
study was delayed for three weeks leading to a small sample size and in addition, the number of 
enrolled patients each week was less than expected.  
The questionnaire was available in Swahili and English and it was administered to participants by 
the research nurse Magdalena Otaro or Dr Philemon. They read the questions out loud and wrote 
down the answers. The clients’ numbers were converted to a study id and this list was safely 
stored in a password protected computer.  
The questionnaire contained questions regarding social and economic status, HIV status, previous 
and current participation in PMTCT programme, current ART (including adherence), side effects 
of ART, knowledge of ART and PMTCT recommendations, and infant feeding methods. 
Information was also gathered from medical charts about previous participation in PMTCT 
programme, ART prophylaxis, the woman’s immune status, and HIV status of the children. 
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5.4 DEFINITIONS:  
Adherence was defined as number of missed doses during the last week and good adherence as an 
intake of 95% or more of the doses. 
5.5 DATA ANALYSIS AND STATISTICAL METHODS:  
Data was analysed with descriptive statistics in SPSS. Frequency tables were used to describe 
patients’ characteristics. To calculate mean and median values, the Mean-tool in SPSS was used. 
Chi-Square test with Fisher’s Exact Test (Exact Sig, 2-sided) was used for univariate data to 
evaluate correlations between variables. P-values < 0.05 were considered statically significant.  
 
6. ETHICS  	
Participation in the study was completely voluntary. All women were given oral information 
about the study and thereafter gave their consent. There were no differences in the care and 
treatment of participants and non-participants. The primary study, which my study was 
incorporated into, received ethical approval from KCMU collage research ethics committee as 
well as permission from the Moshi Municipal Council, and the administration of the respective 
institutions. 
7. RESULTS 
7.1 CHARACTERISTICS OF THE PARTICIPANTS   
Twenty-one women were included in the study. Participant characteristics are shown in table 1. 
Eleven women from KCMC and ten from Pasua Health Centre were included. Median age of the 
participants was 30 and most of the women were employed or self-employed (in total 13/21). 
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One third of the women were married and 11/21 of the women had only finished primary school* 
and did not have any higher education. Christianity was the most common religion (16/21).  
Table 1. Characteristics of the 21 participants.  
Median	Age	 		 30	(Range	18-40)	
Study	site	 PMTCT	KCMC	 11	(52)	
	 Pasua	 10	(48)	
Marital	status	 Married	 7	(33)	
	 Single	 5	(24)	
	 Co-habiting	 3	(14)	
	 Separated	 3	(14)	
	 Widow	 2	(10)	
	 Divorced	 1	(5)	
Occupation	 Self-employed	 7	(33)	
	 Employed	 6	(29)	
	 Housewife	 3	(14)	
	 Unemployed	 3	(14)	
	 Student	 1	(5)	
	 Other	 1	(5)	
Education	level		 Never	been	to	school	 1	(5)	
	 Primary	school	(finished)	 11	(52)	
	 Secondary	school	for	4	years	 5	(24)	
	 Secondary	school	for	6	years	 1	(5)	
	 Vocational	college	 1	(5)	
	 University	 2	(9)	
Current	residence		 Village	 12	(57)	
	 Urban		 9	(43)	
Religion	 Protestant	 9	(43)	
	 Catholic	 7	(33)	
	 Muslim	 4	(19)	
	 Other		 1	(5)	
	   
Data given as numbers (%).   
  
* Seven years of primary school in Tanzania (age 7-13) (36).  
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7.2 HIV, ANTIRETROVIRAL THERAPY, AND SIDE-EFFECTS 
The women had been diagnosed with HIV in median 46 months ago and the majority (13/21) had 
been tested at a health facility, primarily as a part of a PMTCT programme. The median number 
of living children per women was two. Two mothers had an HIV infected child and 2/44 of all 
children to the women included in the study were infected (Figure 1).  
Figure 1. Proportions of HIV infected children among the children to the women included in the study. 
The numbers are number of children. 
Almost all (20/21) participants were on first-line therapy and the most common therapy was TLE 
(Tenofovir, Lamivudine, Efavirenz), only one patient was on second-line therapy. Resistance-
testing was not done in any patient. Side-effects were reported in eight of the participants. Lack 
of energy and abnormal sensation were the most common side-effects. CD4-levels were collected 
in 11/21 of the patients and the median level was 500 cells/µL. Viral loads were also available in 
11/21 of the participants and nine of those had undetectable viral levels.  
 
42
95.5%
2
4.5%
HIV infected children 
Non-infected
Infected
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7.3 ADHERENCE TO ART 
Nineteen women were adherent to their medication during the previous week (Figure 2). The 
women on both first- and second-line therapy had seven doses per week. For the two women with 
sub-optimal adherence, the reasons for sub-optimal adherence were “ran out of pills” and “had no 
food”.  
 
 
Figure 2. Number of missed doses during last week. All women were prescribed one dose per day (seven 
doses per week). Two women had sub-optimal adherence (one and two missed doses). 
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7.4 PARTICIPATION IN PMTCT PROGRAMME  
CURRENT PARTICIPATION 
The vast majority (18/21) of the women were within the first year after childbirth and 11/21 were 
already on ART when they became pregnant (Table 2). Median time since last delivery was 44 
days and 11/21 of the women were attending PMTCT in addition to CTC. 
Table 2. Current participation in PMTCT programme – characteristics.  
Pregnancy	status	 First	year	after	delivery	 18	(86)	
	 Pregnant	 2	(9)	
	 I	don't	know	 1	(5)	
PMTCT	alone	or	in	addition	to	another	clinic	 PMCTC	and	CTC	 11	(52)	
	 PMTCT	alone	 8	(38)	
	 PMTCT	and	antenatal	clinic	 2	(10)	
ART	when	became	pregnant	 Yes	 11	(52)	
	 No	(started	in	week	XX	*)	 10	(48)	
	
*Median	gestational	week	of	
starting	with	ART	
16	
Data given as numbers (%).    
  
PREVIOUS PARTICIPATION 
Eight women had previously participated in a PMTCT programme and among those, two had 
ended prematurely (Figure 3). The reasons for ending prematurely were “My partner was sick” 
and “I lost the pregnancy”. Among the eight women with previous participation, four had 
participated more than one time before (one missing value).  
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Figure 3. Proportions of previous participation in a PMTCT programme among the women attending the 
current PMTCT programme. The numbers are number of women. 
 
There was no significant difference in ART adherence among women participating in the 
PMTCT programme for the first time (no previous participation) compared to those who had 
participated before (p = 0.51) (Table 3). The two women with sub-optimal adherence had not 
participated in a PMTCT programme before.  
Table 3. Previous participation and adherence. Good adherence was considered to be an intake of 95% or 
more of the doses during the previous week.  
	  Adherence	 Total	
	  Adherent	 Non-adherent	 		
Previous	participation	 Count	 8	 0	 8	
		 %		 100%	 0%	 100%	
No	previous	participation	 Count	 11	 2	 13	
		 %		 84.6%	 15.4%	 100%	
Total	 Count	 19	 2	 21	
	 %		 90.5%	 9.5%	 100%	
*P-value	0.51	 	    
  
6
28.6%
2
9.5%
13
61.9%
Previous participation in PMTCT programme
Previous participation (completed 
the programme)
Previous participation (ended 
prematurely)
No previous participation
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Likewise, there was no significant difference in the HIV status of the children among mothers 
participating in the PMTCT programme for the first time compared to those who had participated 
before (p = 1.00). 
7.5 KNOWLEDGE OF ART AND PMTCT PROGRAMMES 
The knowledge of ART and PMTCT programmes was in general good. Almost all women 
(20/21) knew that they are supposed to take their medication lifelong and 12/21 of the women 
knew that HIV can be transmitted from mother to child during both pregnancy, delivery, and 
breastfeeding. The majority (20/21) of women knew that a newborn infant should receive 
exclusive breastfeeding, furthermore two women also thought that warm water or porridge were 
suitable feedings.  
The overall knowledge of each woman was analysed by reconstructing the three questions 
examining the knowledge of ART and PMTCT programmes to three new variables with only 
correct/wrong answers. The woman’s knowledge was considered good if two thirds of the 
questions were answered correctly. According to this definition 19/21 of the women had good 
knowledge of ART and PMTCT programmes. The majority (19/21) of the women wanted to 
learn more in the PMTCT programme. The areas in which the women especially wanted more 
information in the PMTCT programme were HIV treatment and AIDS, education about HIV, and 
breastfeeding. 
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8. DISCUSSION	
8.1 FINDINGS 
PRIMARY FINDINGS 
Participation in a PMTCT programme has been offered to all pregnant women with HIV in 
Moshi, Tanzania since 2004, but the outcome of the programme has previously not been 
evaluated. One of the main findings of this study is that 19/21 of the women (90%) coming for 
follow up in the PMTCT programme reported that they were adherent to their treatment during 
the last week, which is a very good number compared to previous studies. One study from 
Malawi in 2016 found that 73% of the pregnant women and 66% of the post-partum women were 
adherent. They used a different definition of adherence than we did. Adherence was defined as 
percentage of days the women followed their medical prescription (between clinical visits and 
with set time intervals of 3 months and 2 years) and good adherence was defined as > 90% of the 
days (37). In a study from Zambia in 2015, 83% of the pregnant women and 82% of the women 
six weeks post-partum were adherent. The definition for adherence they used was more similar to 
ours. They defined non-adherence as missing a drug or not following the medical prescription 
during the last four days (38). The different definitions of adherence used in studies makes it 
difficult to directly compare them with each other, but the self-reported adherence in our small 
population was very good. Generally, it has been shown that there is a higher risk of sub-optimal 
adherence during the post-partum period compared to non-pregnant and non-post-partum periods 
in a woman’s life (39). 
One problem with using self-reported adherence is that the percentage of participants with good 
adherence may be overestimated. Only half of the women in our study had a documented viral 
load and the date of the test was not known, so we cannot compare the self-reported adherence to 
 21 
viral loads. Two participants had elevated viral loads, but since we do not know the date we do 
not know if it was during pregnancy or not. In another study from Tanzania it was shown that 
many mothers do not disclose suboptimal adherence until they are confronted with their viral 
loads (40). 
We also found that only eight women had participated in a PMTCT programme before, a number 
which was surprisingly low considering that 15/21 of them had children prior the participation in 
the current PMTCT programme. One explanation for this could be that many women attending 
the PMTCT programmes in Pasua and KCMC are unaware of their attendance in the programme 
making it hard for them to remember previous participations. The reason for this is that since 
2013, all pregnant and breastfeeding women are on lifelong ART and regular follow ups which 
makes the conversion from attendance in their regular HIV clinic to the PMTCT clinic more 
unnoticed. 
ADHERENCE AND PREVIOUS PARTICIPATION IN PMTCT PROGRAMMES 
Our hypothesis was that women with previous participation in PMTCT programmes would have 
better adherence since they may have increased knowledge about HIV and HIV prevention than 
women attending the PMTCT programme for the first time. Surprisingly, we did not find a 
significant difference in ART adherence between women with previous PMTCT participation 
compared to women without. The small sample size is most likely one reason for this. Another 
explanation could be that information about HIV and the importance of adherence to lifelong 
ART has increased in the general population. Also, the unawareness of the conversion to a 
PMTCT programme mentioned above may be one reason. To our knowledge, there are no 
published data on this specific issue with ART adherence among women with previous PMTCT 
participation compared to women without. 
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Unfortunately, we did not have information on how many women that did not turn up at their 
PMTCT visits, or the reason for them not coming to their visits. The clinics do not have a list of 
patients so the doctors do not know how many patients are supposed to attend each day. One 
reason for non-attendance may be that their ART adherence is sub-optimal and that they do not 
want to reveal this to the doctor. This is one of the limitations with the study.  
Among the eight women who had participated in a PMTCT programme before, six women (75%) 
completed the entire programme. In a meta-analysis from 2017, the rate of retention to care 
among women attending PMTCT programmes was less than rates among adults in general (41). 
Another study found that nearly 50% of the women initiating ART during pregnancy had missed 
a visit or were lost to follow up from the clinic six months postpartum (42).  In Nigeria, only 66% 
of the women entering PMTCT programmes completed the programme with antenatal care, 
delivery services, and infant follow-up (43). Potential causes for the reasonably high percentage 
of completion in my study are; long time since the previous PMTCT programme makes it hard to 
remember completion/non-completion, the patient does not want to admit that she ended 
prematurely, and an answer from just one patient can affect the percentage a lot with this small 
sample size. Since only two women ended their PMTCT participation prematurely, no risk-
factors for non-completion could be analysed. In addition, one of the women who ended 
prematurely did so because she “lost the pregnancy” which is not a “true” drop out, making the 
number of women completing the entire PMTCT programme even higher. 
HIV STATUS OF THE CHILDREN  
Two of the women had an HIV infected child and 2/44 (4.5%) of the children to all women were 
infected. There was no difference in HIV status of the children among women with previous or 
first participation in the PMTCT programme. In one study, the percentage of HIV infected infants 
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was 3% among women attending PMTCT care during antenatal or delivery periods and 20% 
among those who did not attend (43). This is comparable to another study where 2% of the 
infants to women attending PMTCT care were infected at the end of the PMTCT programme 
(44). Since the HIV status of the newborn infants was not known in this study, we cannot 
compare the numbers with previous studies. 
SOCIODEMOGRAPHIC FACTORS AND KNOWLEDGE OF ART AND PMTCT PROGRAMMES  
A high number (19/21) had good knowledge of ART and PMTCT programmes. This high 
number is an indication of a successful way of teaching this patient group about ART and 
PMTCT programmes in the health centres. Since there were only two women with suboptimal 
adherence we could not do any estimations of correlation between adherence and the following 
variables: education level, age, occupation, and knowledge of ART and PMTCT programmes. 
But current research about adherence to ART have showed some correlations between adherence 
and these variables. For example, a systematic review demonstrated that sub-optimal knowledge 
of HIV, ART, and PMTCT among pregnant and post-partum women were associated with lesser 
initiation, adherence, and retention to care (28). In addition, a study from Ghana showed that 
women with sub-optimal knowledge of ART and PMTCT had a higher risk of poor adherence to 
ART (27). Some previous studies have also shown that young age is a risk factor of sub-optimal 
ART adherence (37, 45). Lower education level has also been shown to be a risk factor for sub-
optimal ART adherence (46).  
8.2 METHODOLOGICAL CONSIDERATIONS 
We constructed a semi-structured questionnaire since this would be an adequate way of 
answering the hypothesis of my master thesis. Unfortunately, many obstacles occurred during the 
field study. One of the major complications was that my ethical application was denied so I could 
not participate in the distribution of the questionnaires. Consequently, patients and interviewers 
 24 
could not ask me directly what I meant if there were any complicated questions even though we 
went through all questions carefully prior to initiation of the study. Due to the denial of the 
ethical approval the start of the field study was delayed for three weeks leading to a small sample 
size and in addition, the number of enrolled patients each week was less than expected. We had 
calculated in including a minimum of 50 participants, but ended up with 21. This is of course the 
biggest weakness with the study. If we had managed to include 92 women in this study we would 
have been able to see a difference between women with good adherence with previous 
participation in a PMTCT programme compared to women with good adherence with no previous 
participation (power = 0.8 and p-value < 0.05).  
In addition, a few misinterpretations concerning some questions in the questionnaire was revealed 
during the second week leading to exclusion of these questions. Question number 17, 20, 23, 34, 
and question number 2 and 3 in “Information gathered from medical charts” were excluded (see 
Appendices, “Mothers interview questionnaire”). Other limitations of the study were that there 
were two interviewers and that the study took place in two health centres making the settings of 
filling in the questionnaires diverse. 
The strengths of this study were that information was collected direct from the mothers, that the 
mothers could ask the interviewer if they had problems understanding the questions, and that the 
collected data was rather homogenous.   
8.3 FURTHER RESEARCH 
The two women with sub-optimal adherence had not participated in a PMTCT programme 
before, but no significant correlation between ART adherence and previous participation in a 
PMTCT programme was found. To test my hypothesis more appropriately and possibly receive a 
significant correlation in future studies, the number of participants must be greater. If an 
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additional hospital was included or the length of the study was increased, this could have been 
achieved. Furthermore, the questionnaire should be tested with some patients before it is used in 
the actual study.  
During this study, questions and new aims were created. Firstly, it would be interesting to 
investigate if there are other factors that affect ART adherence among women attending the 
PMTCT programme in Moshi. For example, one could investigate if other diseases among the 
women affect ART adherence and if there are any differences between the health clinics. Since 
we could not receive any information on the number of women that did not turn up at their 
PMTCT visits, it would be interesting to receive data on this and their reason for non-attendance. 
Another question that would be interesting to investigate is how the adherence to ART differs if 
you do a study using pill-count instead of self-reported adherence.  
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9. CONCLUSIONS 
	
One of the main conclusions of this study was that adherence rate among the women attending 
the PMTCT programme in Pasua health centre and KCMC, in Moshi, Tanzania, is high. Also, 
women attending the PMTCT programme in Pasua Health centre and KCMC, have good 
knowledge of ART and PMTCT programmes. No correlation between previous participation in 
PMTCT programme and ART adherence was found. Neither, no significant difference on the 
child’s/children’s HIV status between mothers with previous participation in PMTCT 
programmes compared to mothers with no previous participation was found.  
Since the number of participants in this study was low, no general conclusions can be drawn from 
these results. Nonetheless, the results can be used to create new aims for further research on ART 
adherence among women attending PMTCT programme.  
Since the adherence rate and knowledge of ART and PMTCT programmes in Moshi is high, 
several actions have already been done for this patient group. To improve the adherence to ART 
and further decrease the MTCT, several actions can be done. Since 19/21 of the women wanted 
to learn more in the PMTCT programme, there are great opportunities to increase knowledge in 
this patient group. Increased knowledge may lead to increased ART adherence and decrease 
stigma in the society. Furthermore, nearly half of the women were not on ART when they 
became pregnant and of those the median gestational week of starting with ART was week 16. 
This could be improved by increased knowledge among the women to make them come to ANC 
directly when they know they are pregnant and take a HIV test. 
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10. POPULÄRVETENSKAPLIG SAMMANFATTNING PÅ SVENSKA 
 
Hög följsamhet till HIV-medicinering bland HIV-positiva kvinnor i norra Tanzania 
Globalt sett är HIV/AIDS en av huvudorsakerna till dödlighet bland kvinnor i reproduktiv ålder. 
För att förhindra att HIV-infektionen förs över till barnet är det viktigt att mammorna har hög 
följsamhet till sin HIV-medicinering då låga, icke-mätbara virusnivåer drastiskt minskar risken 
för överföring under graviditet, förlossning och amning. Det är viktigt att ha kunskap kring 
kvinnors följsamhet till HIV-medicinering för att sjukvården ska kunna sätta in riktade åtgärder.  
För att undersöka detta gjordes en studie på två HIV-kliniker i Moshi i norra Tanzania. Studien 
gick ut på att undersöka om kvinnor som lever med HIV och tidigare har deltagit i ett program 
för att förhindra överföring av HIV till sitt barn (PMTCT program), har bättre följsamhet till sin 
HIV-medicinering än kvinnor som inte har deltagit i detta program tidigare. Med följsamhet 
menas att patienten följer ordinationen och tar rätt mediciner vid rätt tidpunkt. Definitionen på 
god följsamhet är vedertagen och innebar att minst 95% av doserna skulle ha intagits under 
föregående vecka. Mammorna intervjuades med hjälp av en enkät och journalinformation 
samlades in som komplement.  
Tjugoen kvinnor deltog i studien varav nitton (90%) hade god följsamhet till sin HIV-
medicinering. De två kvinnor som hade bristfällig följsamhet angav ”medicinen tog slut” och 
”hade ingen mat” som anledningar till bristande följsamhet. Åtta kvinnor (38%) hade deltagit i ett 
PMTCT program tidigare och av dessa hade två kvinnor avbrutit programmet i förtid. 
Slutsatserna man kan dra av denna studie är att följsamheten till HIV-medicinering bland HIV-
positiva kvinnor i Moshi är hög. Kvinnor som tidigare hade deltagit i ett PMTCT program hade 
inte bättre följsamhet till sin HIV-medicinering än kvinnor som deltog för första gången. Dock 
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var antalet patienter som deltog i studien lågt och det är möjligt att man skulle fått andra resultat 
om antalet patienter hade varit högre.  
Resultaten i denna studie kan användas för att skapa nya frågeställningar till framtida studier på 
denna patientgrupp. Ökad kunskap kring kvinnors följsamhet till HIV-medicinering är viktigt för 
att kunna sätta in riktade åtgärder, öka följsamhet till HIV-medicinering och på så sätt kunna 
minska risken för överföring av HIV från mamma till barn.  
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13. APPENDICES  
 
MOTHERS INTERVIEW QUESTIONNAIRE  
QUESTIONNAIRE NUMBER   
STUDY ID NUMBER   
STUDY SITE  
DATE OF ENROLMENT  
CLIENT NUMBER    
GENERAL INFORMATION 
1. Mothers date of birth  
2. Occupation  Employed 
 House wife 
 Self employed 
 Student 
 Retired 
 Other 
3. Level of education  Never been to school 
 Finished primary education 
 Not finished primary education 
 Secondary school for 4 years 
 Secondary school for 6 years 
 Vocational college  
 University 
4. Marital status  Married 
 Single  
 Cohabiting 
 Separated 
 Divorced 
 Widow 
5. Residence  Village 
 Urban 
6. Religion  Muslim 
 Catholic 
 Protestant 
 Pagan/none 
 Other religion  
7. Time to reach facility from home (in minutes): 
8. Means of transportation to getting to 
facility 
 Walking 
 Motorcycle  
 Bus 
 Taxi 
 Private car 
 Other means of transportation
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HISTORY OF HEALTH 
9. When were you diagnosed with HIV?  
10. How did you find out your status?  Tested at health facility 
 Tested at VCT 
 Tested at campaign 
 Other 
11. What drove you to get tested?  I was asked 
 I asked to be tested 
 My partner had been infected 
 Routine testing at the clinic 
 Part of PMTCT 
 Other (please specify) 
12. Pregnancy status  I am pregnant 
 I was pregnant within the past year) 
 I don’t know 
13. Number of living children  
14. Number of infected children  
 
PREVIOUS PMTCT ENCOUNTERS 
15. Have you participated in PMTCT 
previously? 
 Yes 
 No 
16. How many times have you participated in 
a PMTCT programme? 
 
17. Before your current pregnancy/delivery, 
when was the last time you participated in 
PMTCT? 
 
18. Did you stop PMTCT prematurely?  Yes, go to question 19 
 No, skip question 19 
19. If yes, why?  Didn’t have time 
 Far from home 
 I didn’t think it was a good program 
 Fear of stigma 
 Other 
20. Since your last pregnancy, could you go 
on and use ARVs without stopping? 
 Yes 
 No 
 
CURRENT PARTICIPATION IN PMTCT PROGRAMME 
21. When did you start PMTCT for the 
current pregnancy? 
 
Month Year 
22. Do you have a clinic for PMTCT only or 
in addition to another clinic? 
 PMTCT only 
 PMTCT and antenatal clinic 
 PMTCT and CTC 
 PMTCT and others 
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23. Since you started the current PMTCT 
programme, how many times have you 
attended? 
 
 
ANTIRETROVIRAL THERAPY 
24. What ARVs are you taking? (please, 
specify all of them) 
  
25. Date of starting current regimen  
26. In the past week, how many times did you 
miss your medication? 
 
27. If you have missed any medication, what 
was the reason? (Multiple answers are 
possible) 
 I ran out of pills 
 Forgot/left medicines at home 
 I had a lot of medication to take 
 I was afraid of side effects 
 I was sick 
 Couldn’t afford it 
 I didn’t want anyone to see me taking the 
drugs 
 Other (please specify) 
28. Were you on ARV when you got 
pregnant? If no, when during pregnancy 
did you start? 
 I was on treatment when I got pregnant. 
 No, I started when I was in week 
_____________ of my pregnancy 
29. Were you on ARV during your last 
breastfeeding period? 
 No, none at all 
 Yes, every day 
 Yes, part of the time during breastfeeding 
 
SIDE-EFFECTS 
30. Have you experienced any side-effects of 
the ARVs? 
 Lack of energy 
 Myalgia 
 Skin disease 
 Insomnia 
 Loss of appetite 
 Depression 
 Loss of libido 
 Diarrhea 
 Headache 
 Skin rash 
 Losing weight 
 Anaesthesia/abnormal sensation 
 Others (please specify) 
 None 
 
BREASTFEEDING 
31. Date of last delivery?  
32. Did you breastfeed after delivery?  Yes 
 35 
 No, (If you answered "No", please go to 
question 36) 
 This is my first pregnancy (If you 
answered, “This is my first pregnancy”, 
please go to question 36) 
33. If you answered "Yes", for how long did 
you breastfeed? (Please specify in 
months) 
 
34. If you answered “Yes”, can you specify 
the duration of exclusive breastfeeding 
and the duration of breastfeeding in total 
after your previous delivery? 
 Exclusive breastfeeding (in 
months)_________ 
 Breastfeeding in total (in 
months)_________  
35. If you answered "Yes", was the baby 
tested for HIV after you finished 
breastfeeding? 
 Yes 
 
 No 
 
 Still breastfeeding 
 
KNOWLEDGE OF ANTIRETROVIRAL THERAPY AND PMTCT PROGRAMMES 
36. For how long do you think you have to 
take your HIV drugs? (choose one option) 
 2 months 
 2 years 
 Life long 
 Until I have no symptoms/ my health is 
good 
 As long as the doctor tells me 
 I don’t know 
 Other (please specify) 
37. What more would you like to see being 
done at PMTCT programme? (you can 
choose more than one option) 
 Information/ message about treatments 
and effects of AIDS  
 Family planning counselling 
 Education about HIV and AIDS 
 Information about pregnancy 
 Information about delivery 
 Care of an infant with HIV 
 Information on how to breastfeed 
 How to deal with those who stigmatise 
me 
 Other (please specify) 
38. When can HIV be transmitted from 
mother to child? (You can choose more 
than one option) 
 During pregnancy 
 By sharing bottled water 
 During breastfeeding 
 During changing diapers 
 During delivery 
39. If you have taken your ARV and you 
have a very small child, how will you 
 Exclusive breastfeeding 
 Alternative feeds 
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feed the child? (You can choose more 
than one option) 
 Alternative milk 
 Solid food 
 Others (please specify) 
 
Information gathered from medical charts: 
1. Immune status of the mother:    
 Most recent CD4   
 Viral load    
 Has any resistance testing  been 
performed? 
 Yes  No 
2. Previous participation in PMTCT programme - last time 
 ART prophylaxis   Yes   No 
 ART prophylaxis during 
 delivery 
 Yes   No 
 ART prophylaxis during 
 breastfeeding 
 Yes   No 
3. Previous participation in PMTCT programme – last time (if possible) 
 Duration   Completed program  
 Ended prematurely 
 Number of visits during 
 pregnancy 
 
4. HIV status of Children  
 Number of HIV positive 
 children if possible 
 
 
 
